Now we have Prurisol added to the mix of buyouts 2017. I personally would like to see Pruisol priced dependent on PASI scores. The higher the score the higher the valuation, if we hit biologic realm of 80-90 in 40%, 75-80 in 60% we will get 5-8B then take B&K through phase 3. B-UP,B-OM could be licensed out as separate indications only while the company delves deeper in further Brilacidin capabilities.